Toll-like receptors in systemic autoimmune disease

[1]  S. Akira,et al.  DNA and RNA autoantigens as autoadjuvants , 2006, Journal of endotoxin research.

[2]  J. Shupe,et al.  Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. , 2006, Immunity.

[3]  S. Akira,et al.  Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. , 2006, Immunity.

[4]  T. Winkler,et al.  Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE. , 2006, International immunology.

[5]  P. Courville,et al.  Role of TLR9 in Anti-Nucleosome and Anti-DNA Antibody Production in lpr Mutation-Induced Murine Lupus1 , 2006, The Journal of Immunology.

[6]  T. Roberts,et al.  Higher‐order CpG‐DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice , 2006, European journal of immunology.

[7]  Quanzhen Li,et al.  A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Satterthwaite,et al.  Autoreactive B Cell Responses to RNA-Related Antigens Due to TLR7 Gene Duplication , 2006, Science.

[9]  L. Joosten,et al.  Identification of Small Heat Shock Protein B8 (HSP22) as a Novel TLR4 Ligand and Potential Involvement in the Pathogenesis of Rheumatoid Arthritis1 , 2006, The Journal of Immunology.

[10]  L. Rönnblom,et al.  Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA. , 2006, Arthritis and rheumatism.

[11]  Marta E Alarcón-Riquelme,et al.  A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus , 2006, Nature Genetics.

[12]  S. Akira,et al.  U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. , 2006, Blood.

[13]  B. Becher,et al.  Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. , 2006, The Journal of clinical investigation.

[14]  P. Lenert.  Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus , 2006, Arthritis research & therapy.

[15]  S. Peng,et al.  Toll-like receptor 9 signaling protects against murine lupus. , 2006, Arthritis and rheumatism.

[16]  R. Medzhitov,et al.  Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA , 2006, Nature Immunology.

[17]  A. Aderem,et al.  TLR 9 / MyD 88 signaling is required for class switching to pathogenic IgG 2 a and 2 b autoantibodies in SLE , 2006 .

[18]  A. Aderem,et al.  TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. , 2006, The Journal of experimental medicine.

[19]  S. Akira,et al.  Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8 , 2005, The Journal of experimental medicine.

[20]  H. S. Warren,et al.  Toll-like receptors. , 2005, Critical care medicine.

[21]  F. C. Gibson,et al.  Sensitization of Human Aortic Endothelial Cells to Lipopolysaccharide via Regulation of Toll-Like Receptor 4 by Bacterial Fimbria-Dependent Invasion , 2005, Infection and Immunity.

[22]  S. Akira,et al.  RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement , 2005, The Journal of experimental medicine.

[23]  G. Prestwich,et al.  Regulation of lung injury and repair by Toll-like receptors and hyaluronan , 2005, Nature Medicine.

[24]  H. Anders,et al.  G-rich DNA suppresses systemic lupus. , 2005, Journal of the American Society of Nephrology : JASN.

[25]  S. Akira,et al.  Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus , 2005, The Journal of experimental medicine.

[26]  S. Akira,et al.  Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. , 2005, The Journal of clinical investigation.

[27]  R. Gay,et al.  RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. , 2005, Arthritis and rheumatism.

[28]  Houping Ni,et al.  Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. , 2005, Immunity.

[29]  S. Akira,et al.  Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus , 2005, The Journal of experimental medicine.

[30]  J. Andersen,et al.  TLR11 Activation of Dendritic Cells by a Protozoan Profilin-Like Protein , 2005, Science.

[31]  T. Giese,et al.  Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN , 2005, The Journal of Immunology.

[32]  M. Peterson,et al.  Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. , 2005, Arthritis and rheumatism.

[33]  D. Golenbock,et al.  The Interferon Regulatory Factor, IRF5, Is a Central Mediator of Toll-like Receptor 7 Signaling* , 2005, Journal of Biological Chemistry.

[34]  K. Honda,et al.  Spatiotemporal regulation of MyD88–IRF-7 signalling for robust type-I interferon induction , 2005, Nature.

[35]  A. Marshak‐Rothstein,et al.  Toll‐like receptors, endogenous ligands, and systemic autoimmune disease , 2005, Immunological reviews.

[36]  T. Giese,et al.  Plasmacytoid Dendritic Cells Control TLR7 Sensitivity of Naive B Cells via Type I IFN1 , 2005, The Journal of Immunology.

[37]  A. Rosen,et al.  Generation of novel covalent RNA-protein complexes in cells by ultraviolet B irradiation: implications for autoimmunity. , 2005, Arthritis and rheumatism.

[38]  J. Goeken,et al.  Sequence requirements for oligodeoxyribonucleotide inhibitory activity. , 2005, International immunology.

[39]  Tak W. Mak,et al.  Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors , 2005, Nature.

[40]  V. Pascual,et al.  Defective B cell tolerance checkpoints in systemic lupus erythematosus , 2005, The Journal of experimental medicine.

[41]  J. Kere,et al.  Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. , 2005, American journal of human genetics.

[42]  D. Golenbock,et al.  Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. , 2005, The Journal of clinical investigation.

[43]  K. Ishii,et al.  Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. , 2005, Arthritis and rheumatism.

[44]  S. Akira,et al.  Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease , 2005, Nature Medicine.

[45]  B. Beutler,et al.  TYPE I INTERFERONS (/) IN IMMUNITY AND AUTOIMMUNITY , 2005 .

[46]  Sheng-Nan Lu,et al.  High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies. , 2005, The Journal of rheumatology.

[47]  M. McClain,et al.  Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry , 2005, Nature Medicine.

[48]  S. Akira,et al.  U 1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR 7 , 2005 .

[49]  P. Kubes,et al.  TLR4 Contributes to Disease-Inducing Mechanisms Resulting in Central Nervous System Autoimmune Disease1 , 2004, The Journal of Immunology.

[50]  M. Tsan,et al.  Endogenous ligands of Toll‐like receptors , 2004, Journal of leukocyte biology.

[51]  S. Akira,et al.  Toll-like Receptor 9–Dependent and –Independent Dendritic Cell Activation by Chromatin–Immunoglobulin G Complexes , 2004, The Journal of experimental medicine.

[52]  L. Rönnblom,et al.  Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. , 2004, Arthritis and rheumatism.

[53]  B. Beutler,et al.  TLR7: A new sensor of viral infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[54]  V. Pascual,et al.  Autoimmunity through cytokine-induced dendritic cell activation. , 2004, Immunity.

[55]  J. Simon,et al.  Hyaluronan Fragments Stimulate Endothelial Recognition of Injury through TLR4* , 2004, Journal of Biological Chemistry.

[56]  Akiko Iwasaki,et al.  Recognition of single-stranded RNA viruses by Toll-like receptor 7. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[57]  V. Kuchroo,et al.  Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. , 2004, The Journal of clinical investigation.

[58]  Shizuo Akira,et al.  Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA , 2004, Science.

[59]  M. Greenblatt,et al.  A Toll-like Receptor That Prevents Infection by Uropathogenic Bacteria , 2004, Science.

[60]  S. Akira,et al.  Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8 , 2004, Science.

[61]  E. Abraham,et al.  Involvement of Toll-like Receptors 2 and 4 in Cellular Activation by High Mobility Group Box 1 Protein* , 2004, Journal of Biological Chemistry.

[62]  Harald Neumann,et al.  Neuronal injury mediated via stimulation of microglial toll‐like receptor‐9 (TLR9) , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[63]  J. Platt,et al.  Cutting Edge: An Endogenous Pathway to Systemic Inflammatory Response Syndrome (SIRS)-Like Reactions through Toll-Like Receptor 41 , 2004, The Journal of Immunology.

[64]  J. Oyama,et al.  Reduced Myocardial Ischemia-Reperfusion Injury in Toll-Like Receptor 4-Deficient Mice , 2003, Circulation.

[65]  Zihai Li,et al.  Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Osamu Takeuchi,et al.  Toll-Like Receptor-2 Modulates Ventricular Remodeling After Myocardial Infarction , 2002, Circulation.

[67]  M. Shlomchik,et al.  Activation of autoreactive B cells by CpG dsDNA. , 2003, Immunity.

[68]  L. Calabrese,et al.  Induction of Clinical Autoimmune Disease by Therapeutic Interferon-α , 2003, Autoimmunity.

[69]  L. Joosten,et al.  Toll-Like Receptor 2 Pathway Drives Streptococcal Cell Wall-Induced Joint Inflammation: Critical Role of Myeloid Differentiation Factor 88 , 2003, The Journal of Immunology.

[70]  Lukas Hunziker,et al.  Dendritic cell–induced autoimmune heart failure requires cooperation between adaptive and innate immunity , 2003, Nature Medicine.

[71]  R. Zeuner,et al.  Differential signaling by CpG DNA in DCs and B cells: not just TLR9. , 2003, Trends in immunology.

[72]  L. Rönnblom,et al.  FcγRIIa Is Expressed on Natural IFN-α-Producing Cells (Plasmacytoid Dendritic Cells) and Is Required for the IFN-α Production Induced by Apoptotic Cells Combined with Lupus IgG 1 , 2003, The Journal of Immunology.

[73]  M. Nussenzweig,et al.  Predominant Autoantibody Production by Early Human B Cell Precursors , 2003, Science.

[74]  K. Ishii,et al.  Repetitive Elements in Mammalian Telomeres Suppress Bacterial DNA-Induced Immune Activation1 , 2003, The Journal of Immunology.

[75]  A. Krieg.  CpG motifs: the active ingredient in bacterial extracts? , 2003, Nature Medicine.

[76]  G. Hartmann,et al.  Rational design of new CpG oligonucleotides that combine B cell activation with high IFN‐α induction in plasmacytoid dendritic cells , 2003, European journal of immunology.

[77]  M. Iles,et al.  A biologically important single nucleotide polymorphism within the toll-like receptor-4 gene is not associated with rheumatoid arthritis. , 2003, Clinical and experimental rheumatology.

[78]  David A. Hume,et al.  The Molecular Basis for the Lack of Immunostimulatory Activity of Vertebrate DNA1 , 2003, The Journal of Immunology.

[79]  R. Zinkernagel,et al.  Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections , 2003, Nature Immunology.

[80]  Virginia Pascual,et al.  Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.

[81]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[82]  J. Choe,et al.  Interleukin 1 Receptor Dependence of Serum Transferred Arthritis Can be Circumvented by Toll-like Receptor 4 Signaling , 2003, The Journal of experimental medicine.

[83]  A. Krieg,et al.  Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation. , 2003, International immunology.

[84]  J. Witztum,et al.  Minimally Modified LDL Binds to CD14, Induces Macrophage Spreading via TLR4/MD-2, and Inhibits Phagocytosis of Apoptotic Cells* , 2003, The Journal of Biological Chemistry.

[85]  S. Akira,et al.  Toll-like receptors. , 2003, Annual review of immunology.

[86]  P. Plotz,et al.  The autoantibody repertoire: searching for order , 2003, Nature Reviews Immunology.

[87]  G. Cooke,et al.  Toll-like receptor 4 polymorphisms and atherogenesis. , 2002, The New England journal of medicine.

[88]  B. Segal,et al.  Activation of APCs Through CD40 or Toll-Like Receptor 9 Overcomes Tolerance and Precipitates Autoimmune Disease1 , 2002, The Journal of Immunology.

[89]  R. Vabulas,et al.  Bacterial CpG‐DNA and lipopolysaccharides activate Toll‐like receptors at distinct cellular compartments , 2002, European journal of immunology.

[90]  E. Wakeland,et al.  Genetic Modifiers of Systemic Lupus Erythematosus in FcγRIIB−/− Mice , 2002, The Journal of experimental medicine.

[91]  S. Szabo,et al.  T-bet regulates IgG class switching and pathogenic autoantibody production , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[92]  M. Shlomchik,et al.  Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors , 2002, Nature.

[93]  T. Ahrens,et al.  Oligosaccharides of Hyaluronan Activate Dendritic Cells via Toll-like Receptor 4 , 2002, The Journal of experimental medicine.

[94]  Arthur S Slutsky,et al.  Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome , 2002, Critical care medicine.

[95]  A. Krieg,et al.  CpG motifs in bacterial DNA and their immune effects. , 2002, Annual review of immunology.

[96]  H. Schild,et al.  Heat shock proteins as ligands of toll-like receptors. , 2002, Current topics in microbiology and immunology.

[97]  L. Rönnblom,et al.  A Pivotal Role for the Natural Interferon α–producing Cells (Plasmacytoid Dendritic Cells) in the Pathogenesis of Lupus , 2001, The Journal of experimental medicine.

[98]  N. Kadowaki,et al.  Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial Antigens , 2001, The Journal of experimental medicine.

[99]  W. Hancock,et al.  Fibrinogen Stimulates Macrophage Chemokine Secretion Through Toll-Like Receptor 41 , 2001, The Journal of Immunology.

[100]  L. Rönnblom,et al.  An etiopathogenic role for the type I IFN system in SLE. , 2001, Trends in immunology.

[101]  Amer A. Beg,et al.  An Essential Role of the NF-κB/Toll-Like Receptor Pathway in Induction of Inflammatory and Tissue-Repair Gene Expression by Necrotic Cells1 , 2001, The Journal of Immunology.

[102]  Jerome F. Strauss,et al.  The Extra Domain A of Fibronectin Activates Toll-like Receptor 4* , 2001, The Journal of Biological Chemistry.

[103]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[104]  P. Anderson,et al.  Death, autoantigen modifications, and tolerance , 2000, Arthritis research.

[105]  R. Medzhitov,et al.  Innate immune recognition: mechanisms and pathways , 2000, Immunological reviews.

[106]  Andrej Tarkowski,et al.  Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis , 1999, Nature Medicine.

[107]  L. Rönnblom,et al.  Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon‐alpha (IFN‐α) production acting on leucocytes resembling immature dendritic cells , 1999, Clinical and experimental immunology.

[108]  A. Rosen,et al.  Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease , 1999, Cell Death and Differentiation.

[109]  H. Mischak,et al.  CpG‐DNA‐specific activation of antigen‐presenting cells requires stress kinase activity and is preceded by non‐specific endocytosis and endosomal maturation , 1998, The EMBO journal.

[110]  T. Wu,et al.  Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[111]  A. Krieg,et al.  CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. , 1998, Journal of immunology.

[112]  S. Amigorena,et al.  Role of B-cell and Fc receptors in the selection of T-cell epitopes. , 1998, Current opinion in immunology.

[113]  L. Manzel,et al.  Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. , 1998, Journal of immunology.

[114]  R. Jaenisch,et al.  Mitogenicity of DNA from different organisms for murine B cells. , 1997, Journal of immunology.

[115]  K. Herbert,et al.  Immunogenicity of DNA damaged by reactive oxygen species--implications for anti-DNA antibodies in lupus. , 1997, Free radical biology & medicine.

[116]  M. Shlomchik,et al.  A disease-related rheumatoid factor autoantibody is not tolerized in a normal mouse: implications for the origins of autoantibodies in autoimmune disease , 1996, The Journal of experimental medicine.

[117]  G. Bishop,et al.  CpG motifs in bacterial DNA trigger direct B-cell activation , 1995, Nature.

[118]  A. Hoes.  Case-control studies. , 1995, The Netherlands journal of medicine.

[119]  M. Shlomchik,et al.  An isotype switched and somatically mutated rheumatoid factor clone isolated from a MRL-lpr/lpr mouse exhibits limited intraclonal affinity maturation. , 1994, Journal of immunology.

[120]  A. Rosen,et al.  Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes , 1994, The Journal of experimental medicine.

[121]  H. Griffiths,et al.  A marker of oxidative DNA damage in systemic lupus erythematosus , 1994 .

[122]  D. Pisetsky,et al.  Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. , 1991, Journal of immunology.

[123]  S Hanash,et al.  Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. , 1990, Arthritis and rheumatism.

[124]  L. Rönnblom,et al.  Possible induction of systemic lupus erythematosus by interferon‐α treatment in a patient with a malignant carcinoid tumour , 1990, Journal of internal medicine.

[125]  E. Tan,et al.  Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. , 1989, Advances in immunology.

[126]  S. Hanash,et al.  Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. , 1988, Journal of immunology.

[127]  D. Wallace,et al.  Dubois' Lupus Erythematosus , 1987 .

[128]  R. Friedman,et al.  Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. , 1982, Science.

[129]  H. Sano,et al.  Dna isolated from DNA/anti-DNA antibody immune complexes in systemic lupus erythematosus is rich in guanine-cytosine content. , 1982, Journal of immunology.

[130]  I. Emerit,et al.  Mechanism of photosensitivity in systemic lupus erythematosus patients. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[131]  W. J. Morginson.  [Lupus erythematosus]. , 1960, Revista medica hondurena.

[132]  M. Tye,et al.  Lupus erythematosus treated with a combination of quinacrine, hydroxychloroquine and chloroquine. , 1959, The New England journal of medicine.